Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
13 Jun 2022
Historique:
received: 15 02 2022
accepted: 30 05 2022
entrez: 13 6 2022
pubmed: 14 6 2022
medline: 16 6 2022
Statut: epublish

Résumé

The burden of carbapenem resistance is not well studied in the Middle East. We aimed to describe the molecular epidemiology and outcome of carbapenem-resistant Enterobacterales (CRE) infections from several Saudi Arabian Centers. This is a multicenter prospective cohort study conducted over a 28-month period. Patients older than 14 years of age with a positive CRE Escherichia coli or Klebsiella pneumoniae culture and a clinically established infection were included in this study. Univariate and multivariable logistic models were constructed to assess the relationship between the outcome of 30-day all-cause mortality and possible continuous and categorical predictor variables. A total of 189 patients were included. The median patient age was 62.8 years and 54.0% were male. The most common CRE infections were nosocomial pneumonia (23.8%) and complicated urinary tract infection (23.8%) and 77 patients (40.7%) had CRE bacteremia. OXA-48 was the most prevalent gene (69.3%). While 100 patients (52.9%) had a clinical cure, 57 patients (30.2%) had died within 30 days and 23 patients (12.2%) relapsed. Univariate analysis to predict 30-day mortality revealed that the following variables are associated with mortality: older age, high Charlson comorbidity index, increased Pitt bacteremia score, nosocomial pneumonia, CRE bacteremia and diabetes mellitus. In multivariable analysis, CRE bacteremia remained as an independent predictor of 30 day all-cause mortality [AOR and 95% CI = 2.81(1.26-6.24), p = 0.01]. These data highlight the molecular epidemiology and outcomes of CRE infection in Saudi Arabia and will inform future studies to address preventive and management interventions.

Sections du résumé

BACKGROUND BACKGROUND
The burden of carbapenem resistance is not well studied in the Middle East. We aimed to describe the molecular epidemiology and outcome of carbapenem-resistant Enterobacterales (CRE) infections from several Saudi Arabian Centers.
METHODS METHODS
This is a multicenter prospective cohort study conducted over a 28-month period. Patients older than 14 years of age with a positive CRE Escherichia coli or Klebsiella pneumoniae culture and a clinically established infection were included in this study. Univariate and multivariable logistic models were constructed to assess the relationship between the outcome of 30-day all-cause mortality and possible continuous and categorical predictor variables.
RESULTS RESULTS
A total of 189 patients were included. The median patient age was 62.8 years and 54.0% were male. The most common CRE infections were nosocomial pneumonia (23.8%) and complicated urinary tract infection (23.8%) and 77 patients (40.7%) had CRE bacteremia. OXA-48 was the most prevalent gene (69.3%). While 100 patients (52.9%) had a clinical cure, 57 patients (30.2%) had died within 30 days and 23 patients (12.2%) relapsed. Univariate analysis to predict 30-day mortality revealed that the following variables are associated with mortality: older age, high Charlson comorbidity index, increased Pitt bacteremia score, nosocomial pneumonia, CRE bacteremia and diabetes mellitus. In multivariable analysis, CRE bacteremia remained as an independent predictor of 30 day all-cause mortality [AOR and 95% CI = 2.81(1.26-6.24), p = 0.01].
CONCLUSIONS CONCLUSIONS
These data highlight the molecular epidemiology and outcomes of CRE infection in Saudi Arabia and will inform future studies to address preventive and management interventions.

Identifiants

pubmed: 35698046
doi: 10.1186/s12879-022-07507-y
pii: 10.1186/s12879-022-07507-y
pmc: PMC9190113
doi:

Substances chimiques

Anti-Bacterial Agents 0
Carbapenems 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

542

Informations de copyright

© 2022. The Author(s).

Références

J Infect Public Health. 2019 Jul - Aug;12(4):465-471
pubmed: 31060974
BMC Infect Dis. 2019 Sep 4;19(1):772
pubmed: 31484510
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20
pubmed: 23290507
Int J Infect Dis. 2021 Aug;109:1-7
pubmed: 34091006
Virulence. 2017 May 19;8(4):460-469
pubmed: 27593176
Lancet Infect Dis. 2019 Jun;19(6):601-610
pubmed: 31047852
Emerg Infect Dis. 2014 Jul;20(7):1170-5
pubmed: 24959688
Clin Microbiol Infect. 2011 Dec;17(12):1798-803
pubmed: 21595793
Antimicrob Agents Chemother. 2009 May;53(5):1868-73
pubmed: 19223638
Clin Microbiol Infect. 2012 Jan;18(1):54-60
pubmed: 21722257
Lancet Infect Dis. 2018 Dec;18(12):e379-e394
pubmed: 30292478
Open Forum Infect Dis. 2021 Jan 21;8(2):ofab026
pubmed: 33623807
Lancet Infect Dis. 2017 Jul;17(7):726-734
pubmed: 28442293
PLoS One. 2016 Apr 22;11(4):e0154092
pubmed: 27104910
Drugs. 2018 Jan;78(1):65-98
pubmed: 29230684
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27895014
J Pediatric Infect Dis Soc. 2019 Jul 1;8(3):251-260
pubmed: 30793757
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0069821
pubmed: 34228539
Infect Control Hosp Epidemiol. 2008 Dec;29(12):1099-106
pubmed: 18973455
Clin Infect Dis. 2018 Jan 6;66(2):163-171
pubmed: 29020404
Clin Microbiol Rev. 2012 Oct;25(4):682-707
pubmed: 23034326

Auteurs

Basem M Alraddadi (BM)

King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia. balraddadi@kfshrc.edu.sa.
Alfaisal University, Riyadh, Saudi Arabia. balraddadi@kfshrc.edu.sa.

Emily L G Heaphy (ELG)

King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.

Yamama Aljishi (Y)

King Fahd Specialist Hospital, Dammam, Saudi Arabia.

Waleed Ahmed (W)

Security Forces Hospital, Makkah, Saudi Arabia.

Khalid Eljaaly (K)

Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.

Hanan H Al-Turkistani (HH)

King Abdullah Medical City, Makkah, Saudi Arabia.

Abeer N Alshukairi (AN)

King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Alfaisal University, Riyadh, Saudi Arabia.

Mohammed O Qutub (MO)

King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Department of Pathology and Laboratory Medicine Clinical Microbiology Lab, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.

Kholoud Alodini (K)

Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia.

Roaa Alosaimi (R)

King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.

Waseem Hassan (W)

Security Forces Hospital, Makkah, Saudi Arabia.

Dalya Attalah (D)

Clinical Microbiology Laboratory, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.

Rakan Alswaiel (R)

King Fahd Medical City, Riyadh, Saudi Arabia.

Mohammed F Saeedi (MF)

King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.

Mohammed A Al-Hamzi (MA)

King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.

Lama K Hefni (LK)

King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.

Reem S Almaghrabi (RS)

King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Mushira Anani (M)

King Fahd Medical City, Riyadh, Saudi Arabia.

Abdulhakeem Althaqafi (A)

Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH